HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Crescent Pharma Limited Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Crescent Pharma Limited Intelligence Report

Generated from 2 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Jun 25, 2026

Confidence

Moderate Confidence · 78%

Evidence

12 items

Sources

8

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Crescent Pharma Limited maintains an active intelligence profile across Cardiovascular, ACE Inhibitor, Psychiatry, Antidepressant. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 78% across 3 tracked sources. Highest-priority development: Pharmathen International S.A. - 723680 - 05/27/2026. Regulatory precedent. Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Crescent Pharma Limited.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    Pharmathen International S.A. - 723680 - 05/27/2026

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA notification regarding unapproved drugs included in kits

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 44 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Pharmathen International S.A. - 723680 - 05/27/2026

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA notification regarding unapproved drugs included in kits

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Crescent Pharma recalls Ramipril 5mg capsules due to manufacturing error

    Cardiovascular · ACE Inhibitor

  • Cadila Pharmaceuticals Issues Class 4 Defect Notification for Mirtazapine 30mg Tablets

    Psychiatry · Antidepressant

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.